Browse ASPN

Summary
SymbolASPN
Nameasporin
Aliases FLJ20129; SLRR1C; PLAP1; asporin proteoglycan; asporin (LRR class 1); OS3; periodontal ligament associated p ......
Chromosomal Location9q22.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Secreted, extracellular space, extracellular matrix
Domain PF13855 Leucine rich repeat
PF01462 Leucine rich repeat N-terminal domain
Function

Negatively regulates periodontal ligament (PDL) differentiation and mineralization to ensure that the PDL is not ossified and to maintain homeostasis of the tooth-supporting system. Inhibits BMP2-induced cytodifferentiation of PDL cells by preventing its binding to BMPR1B/BMP type-1B receptor, resulting in inhibition of BMP-dependent activation of SMAD proteins (By similarity). Critical regulator of TGF-beta in articular cartilage and plays an essential role in cartilage homeostasis and osteoarthritis (OA) pathogenesis. Negatively regulates chondrogenesis in the articular cartilage by blocking the TGF-beta/receptor interaction on the cell surface and inhibiting the canonical TGF-beta/Smad signal. Binds calcium and plays a role in osteoblast-driven collagen biomineralization activity.

> Gene Ontology
 
Biological Process GO:0001503 ossification
GO:0001933 negative regulation of protein phosphorylation
GO:0006469 negative regulation of protein kinase activity
GO:0007178 transmembrane receptor protein serine/threonine kinase signaling pathway
GO:0007179 transforming growth factor beta receptor signaling pathway
GO:0007259 JAK-STAT cascade
GO:0017015 regulation of transforming growth factor beta receptor signaling pathway
GO:0030282 bone mineralization
GO:0030512 negative regulation of transforming growth factor beta receptor signaling pathway
GO:0031214 biomineral tissue development
GO:0033673 negative regulation of kinase activity
GO:0034505 tooth mineralization
GO:0042326 negative regulation of phosphorylation
GO:0042476 odontogenesis
GO:0042481 regulation of odontogenesis
GO:0042483 negative regulation of odontogenesis
GO:0046425 regulation of JAK-STAT cascade
GO:0046426 negative regulation of JAK-STAT cascade
GO:0051348 negative regulation of transferase activity
GO:0070167 regulation of biomineral tissue development
GO:0070168 negative regulation of biomineral tissue development
GO:0070170 regulation of tooth mineralization
GO:0070171 negative regulation of tooth mineralization
GO:0071559 response to transforming growth factor beta
GO:0071560 cellular response to transforming growth factor beta stimulus
GO:0090092 regulation of transmembrane receptor protein serine/threonine kinase signaling pathway
GO:0090101 negative regulation of transmembrane receptor protein serine/threonine kinase signaling pathway
GO:0090287 regulation of cellular response to growth factor stimulus
GO:0090288 negative regulation of cellular response to growth factor stimulus
GO:0097696 STAT cascade
GO:1902532 negative regulation of intracellular signal transduction
GO:1903844 regulation of cellular response to transforming growth factor beta stimulus
GO:1903845 negative regulation of cellular response to transforming growth factor beta stimulus
GO:1904892 regulation of STAT cascade
GO:1904893 negative regulation of STAT cascade
GO:2000027 regulation of organ morphogenesis
Molecular Function GO:0004857 enzyme inhibitor activity
GO:0004860 protein kinase inhibitor activity
GO:0005518 collagen binding
GO:0019207 kinase regulator activity
GO:0019210 kinase inhibitor activity
GO:0019887 protein kinase regulator activity
Cellular Component GO:0005578 proteinaceous extracellular matrix
> KEGG and Reactome Pathway
 
KEGG -
Reactome R-HSA-3000178: ECM proteoglycans
R-HSA-1474244: Extracellular matrix organization
Summary
SymbolASPN
Nameasporin
Aliases FLJ20129; SLRR1C; PLAP1; asporin proteoglycan; asporin (LRR class 1); OS3; periodontal ligament associated p ......
Chromosomal Location9q22.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between ASPN and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolASPN
Nameasporin
Aliases FLJ20129; SLRR1C; PLAP1; asporin proteoglycan; asporin (LRR class 1); OS3; periodontal ligament associated p ......
Chromosomal Location9q22.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of ASPN in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolASPN
Nameasporin
Aliases FLJ20129; SLRR1C; PLAP1; asporin proteoglycan; asporin (LRR class 1); OS3; periodontal ligament associated p ......
Chromosomal Location9q22.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of ASPN in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-1.4770.0301
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-2.0420.2
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-1.0560.366
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.5470.241
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.6960.669
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.3540.869
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.4030.539
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.420.748
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.1960.904
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.1980.907
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 282.6250.197
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.5170.0428
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of ASPN in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277302.7-2.71
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275903.4-3.41
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolASPN
Nameasporin
Aliases FLJ20129; SLRR1C; PLAP1; asporin proteoglycan; asporin (LRR class 1); OS3; periodontal ligament associated p ......
Chromosomal Location9q22.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of ASPN. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolASPN
Nameasporin
Aliases FLJ20129; SLRR1C; PLAP1; asporin proteoglycan; asporin (LRR class 1); OS3; periodontal ligament associated p ......
Chromosomal Location9q22.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of ASPN. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by ASPN.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolASPN
Nameasporin
Aliases FLJ20129; SLRR1C; PLAP1; asporin proteoglycan; asporin (LRR class 1); OS3; periodontal ligament associated p ......
Chromosomal Location9q22.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of ASPN. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolASPN
Nameasporin
Aliases FLJ20129; SLRR1C; PLAP1; asporin proteoglycan; asporin (LRR class 1); OS3; periodontal ligament associated p ......
Chromosomal Location9q22.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of ASPN expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolASPN
Nameasporin
Aliases FLJ20129; SLRR1C; PLAP1; asporin proteoglycan; asporin (LRR class 1); OS3; periodontal ligament associated p ......
Chromosomal Location9q22.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between ASPN and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolASPN
Nameasporin
Aliases FLJ20129; SLRR1C; PLAP1; asporin proteoglycan; asporin (LRR class 1); OS3; periodontal ligament associated p ......
Chromosomal Location9q22.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting ASPN collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.